Akebia Therapeutics, Inc.
AKBA
$3.19
$0.072.24%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 203.73M | 184.91M | 160.18M | 169.88M | 174.50M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 203.73M | 184.91M | 160.18M | 169.88M | 174.50M |
| Cost of Revenue | 32.92M | 30.51M | 25.06M | 25.86M | 29.81M |
| Gross Profit | 170.81M | 154.40M | 135.12M | 144.02M | 144.69M |
| SG&A Expenses | 106.49M | 106.85M | 106.55M | 104.31M | 100.50M |
| Depreciation & Amortization | 18.02M | 27.03M | 36.04M | 36.04M | 36.04M |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 198.47M | 202.06M | 205.30M | 201.94M | 206.92M |
| Operating Income | 5.26M | -17.15M | -45.12M | -32.06M | -32.43M |
| Income Before Tax | -36.48M | -45.31M | -69.41M | -45.99M | -40.44M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -36.48 | -45.31 | -69.41 | -45.99 | -40.44 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -36.48M | -45.31M | -69.41M | -45.99M | -40.44M |
| EBIT | 5.26M | -17.15M | -45.12M | -32.06M | -32.43M |
| EBITDA | 24.61M | 11.29M | -7.61M | 5.50M | 5.17M |
| EPS Basic | -0.17 | -0.21 | -0.33 | -0.22 | -0.20 |
| Normalized Basic EPS | -0.10 | -0.12 | -0.19 | -0.13 | -0.12 |
| EPS Diluted | -0.17 | -0.21 | -0.33 | -0.22 | -0.20 |
| Normalized Diluted EPS | -0.10 | -0.12 | -0.19 | -0.13 | -0.12 |
| Average Basic Shares Outstanding | 927.11M | 874.25M | 843.71M | 814.91M | 792.87M |
| Average Diluted Shares Outstanding | 941.75M | 880.36M | 843.71M | 815.51M | 793.46M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |